The medication is commonly used to address conditions presenting with significant symptomatic burden across two primary therapeutic domains: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Addressing Symptomatic Dysfunction

The treatment is relevant for easing symptoms that interfere with daily functioning, specifically the inability to get or maintain an erection firm enough for sexual intercourse. It is commonly used to help with all severity levels of ED. This may assist with maintaining functional stability and contributes to improved comfort related to sexual health.

“This therapy is commonly used to offer symptomatic relief that helps patients cope more steadily with functional fluctuations.”

Managing Functional Stress in Pulmonary Hypertension

The active ingredient is applied in addressing a different domain: conditions involving episodic or fluctuating manifestations like the shortness of breath and fatigue associated with PAH. In this context, the therapy provides support that helps ease the overall symptom burden by helping maintain a sense of stability when functional stress is heightened.

Quick Fact: Support for Symptomatic Distress
The treatment is relevant for easing symptoms linked to organ-specific functional stress in two distinct areas where functional stability becomes affected.

Regulatory References

1. Sildenafil: MedlinePlus Drug Information

The eligibility for using Sildenafil (Viagra) is strictly defined by governmental regulatory authorities and is limited only to adult men (18 years and older) with erectile dysfunction. Use is not indicated for women, including those who are pregnant or breastfeeding, or for individuals under 18 years of age.

The medicine is absolutely contraindicated for several populations due to the risk of severe hypotension or other major health events, including:

• Patients concurrently using any form of organic nitrates or nitric oxide donors (e.g., nitroglycerin).
• Individuals with known hypersensitivity to sildenafil or any component of the tablet.
• Men for whom sexual activity is inadvisable due to severe, unstable cardiovascular disorders (e.g., severe cardiac failure).
• Patients with a history of vision loss due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) or known hereditary retinal disorders (e.g., retinitis pigmentosa).

Use is also contraindicated in patients with other severe pre-existing conditions such as severe hepatic impairment (Child-Pugh Class C), severe hypotension (resting blood pressure below 90/50 mmHg), and recent history of stroke or myocardial infarction (within the last six months). A restricted starting dose is officially considered necessary for individuals with severe renal impairment or other forms of hepatic impairment due to reduced drug clearance. Caution is advised for patients with conditions that predispose to priapism or with anatomical deformation of the penis.

Interactions with other medicines and products

Official regulatory documents classify Sildenafil interactions into distinct pharmacological and administrative categories.

Classification	Interacting Agents (Classes / Examples)	Interaction Outcome (Regulatory Description)
Contraindicated Combinations	Organic Nitrates and Guanylate Cyclase (GC) Stimulators (e.g., Riociguat).	Potentially fatal hypotensive effects (pharmacodynamic synergism).
Pharmacokinetic (CYP3A4)	Strong Inhibitors (e.g., Ritonavir, Ketoconazole) and Inducers (e.g., Bosentan).	Inhibitors significantly increase Sildenafil plasma exposure (reduced clearance). Inducers decrease exposure.
Pharmacodynamic Risk	Alpha-blockers and general Anti-hypertensives.	Potentiation of hypotensive effects; may lead to symptomatic low blood pressure.
Administration/Timing	Alpha-blockers; Ritonavir.	Treatment must be initiated at the 25 mg dose when co-administering with alpha-blockers. Ritonavir co-administration limits the Sildenafil dose to 25 mg per 48 hours.

The regulatory interaction profile is structurally defined by an absolute prohibition on combining Sildenafil with potent vasodilators, such as nitrates. Pharmacokinetic concerns center on the drug's clearance via the CYP3A4 enzyme; strong inhibitors, including Ritonavir, dramatically increase drug exposure and mandate strict administration constraints. Additionally, the official labeling notes that a high-fat meal reduces the rate and extent of absorption, and reduced clearance is documented in patients with severe renal or hepatic impairment.

Selective Inhibition of the PDE5 Enzyme

Sildenafil functions as a highly specific competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which regulates vascular tone in the target tissue. By preventing PDE5 from degrading the key signaling molecule cyclic Guanosine Monophosphate (cGMP), the drug mechanically extends the duration and intensity of the natural relaxation signal.

Modulating the Nitric Oxide/cGMP Signaling Cascade

The drug's mechanism is fundamentally dependent on the body's natural response to stimulation, which initiates the release of Nitric Oxide (NO). Sildenafil acts to modulate this cascade by maintaining high levels of cGMP, thereby promoting sustained activity in the relaxation pathway, which facilitates vascular smooth muscle relaxation and vasodilation.

Contingency and Limits on Selectivity

The physiological effect is contingent upon sexual stimulation, meaning the mechanism requires the initiation of the upstream physiological process. A mechanistic constraint is the minor cross-inhibition of the retinal enzyme PDE6, which results in the modulation of the retinal phototransduction cascade.

How to Use Sildenafil: Official Administration Guidelines

Sildenafil is administered based on the condition being treated, defining either an as-needed or a scheduled maintenance regimen. The primary route of administration is oral, available as film-coated tablets for Erectile Dysfunction (ED) and as 20 mg tablets or oral suspension for Pulmonary Arterial Hypertension (PAH). The intravenous (IV) route is reserved for PAH patients temporarily unable to take the medicine orally.

---

Official Dosing and Frequency

Condition	Starting Dose	Maximum Frequency	Administration Timing
Erectile Dysfunction (ED)	50 mg as needed	Once per day	approx 1 hour before activity (30 minutes to 4 hours)
Pulmonary Arterial Hypertension (PAH)	20 mg (oral/IV)	Three times per day (TID)	Scheduled, 4 to 6 hours apart

For ED, the dose may be adjusted from 25 mg up to the 100 mg maximum. Taking the tablet with food may delay the onset of action, and sexual stimulation is necessary for the drug to be effective. For PAH, the dose may be titrated up to 80 mg TID. If a scheduled PAH dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped.

---

Population-Specific Considerations

A lower initial dose of 25 mg is specified for ED in certain populations, including older adults (ge 65 years) and patients with severe renal or hepatic impairment. This initial adjustment is a procedural requirement to govern the starting point for treatment.

Research Evidence / Overview of Studies for Sildenafil (Viagra)

Evidence Base for Erectile Dysfunction (ED)

The research evaluating Sildenafil for Erectile Dysfunction (ED) primarily consists of numerous Randomized Controlled Trials (RCTs). These short-term studies, which were often double-blind and compared Sildenafil to an inactive placebo, were central to the documentation supporting regulatory evaluation.

Researchers enrolled a wide range of adult men with ED stemming from various causes. Studies explored the ability to achieve and maintain an erection firm enough for sexual activity in participants during treatment periods. This was tracked using patient diaries and validated instruments, such as the International Index of Erectile Function (IIEF), which measures patient-reported outcomes.

---

Evidence Base for Pulmonary Arterial Hypertension (PAH)

For Pulmonary Arterial Hypertension (PAH), Sildenafil was studied in distinct Randomized Controlled Trials (RCTs). These studies were necessary because PAH is a complex condition involving functional limitations and physiological strain. Research examined outcomes related to physical discomfort and activity level.

The main outcomes studies monitored were changes in functional capacity, most notably the 6-minute walk distance (6MWD). Trials monitored how patients performed on this functional measure over the study period. Additionally, studies explored hemodynamic measures, which are physiological outcomes related to blood flow and pressure within the heart and pulmonary arteries.

---

Extended Observation and Long-Term Follow-up Data

While the core efficacy research for both ED and PAH was based on short-term trials, studies also explored longer-term experiences. For both indications, many participants were offered the chance to participate in open-label extension studies. This research provides context by following patients for periods of a year or more, observing patient health status over extended intervals. However, because they are unblinded, the data gathered are different in nature compared to the initial short-term RCTs, and often introduce greater research limitations.

---

Areas of Research Uncertainty and Gaps

For the ED indication, the available data are primarily based on the study of on-demand use, meaning the data for continuous or daily use are not as well established in controlled trials. Furthermore, the evidence available for pediatric PAH remains a complex area; findings were mixed across different doses when observing long-term outcomes, indicating that data are still emerging in certain areas of that specific population’s research.

Common questions about Viagra (FAQ)

Q: How long does the effect of sildenafil last?

According to official clinical data, the active ingredient sildenafil has a terminal half-life of approximately four hours. This measurement describes the rate at which the medicine is eliminated from the body. The half-life describes the rate of elimination, and the time until the physiological effect subsides may vary for each individual.

Q: Is it safe to drink alcohol when taking sildenafil?

Regulatory studies examined the effects of sildenafil alongside alcohol consumption in healthy volunteers. Official product information indicates that the medicine did not increase the low blood pressure effects of alcohol when consumed up to a mean maximum blood alcohol level of 0.08%. It is important for individuals to review the official warnings regarding potential low blood pressure effects (hypotension).

Q: Does grapefruit or grapefruit juice interact with sildenafil?

Official drug interaction information notes that grapefruit juice can affect how the body processes sildenafil. Grapefruit juice is an inhibitor of the enzyme that breaks down the medicine. Consuming strong inhibitors, such as grapefruit juice, may lead to increased concentrations of the active ingredient in the bloodstream.

Q: Is it safe to take sildenafil with blood thinners like warfarin?

The official documentation indicates that patients taking sildenafil concurrently with a vitamin K antagonist, which is a type of blood thinner, reported a higher incidence of nosebleed (epistaxis). This finding is included in regulatory warnings as a factor noted for individuals using both medications.

Q: Should I take sildenafil at a specific time of day?

For the treatment of erectile dysfunction, official instructions recommend taking sildenafil approximately one hour before anticipating sexual activity. For erectile dysfunction, the medicine is typically described as an 'as needed' treatment, with official documents specifying a maximum administration frequency of once daily.

Q: Is sildenafil effective for severe erectile dysfunction?

Clinical trials included men with erectile dysfunction of various causes and severities. The efficacy results reviewed for regulatory approval included various patient subgroups. Official documents reflect that response rates varied based on the specific etiology of the condition.

Q: Does smoking interact with sildenafil?

Official warnings mention smoking as an underlying vascular risk factor. Smoking is listed as a potential risk factor for a rare visual side effect known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), reported with this drug class.

Q: Is there an approved fast-dissolving formulation of sildenafil?

In some international jurisdictions, a rapidly disintegrating orodispersible film formulation of sildenafil has been authorized for marketing. This indicates that different formulations have been authorized for marketing in certain regulatory areas.

Q: What is the success rate of sildenafil in clinical trials?

Clinical trials tracked efficacy through validated measures and patient questionnaires. In Phase III clinical trials, the response rate to the overall efficacy question varied. The highest rates of improvement were often observed in patient groups whose condition was attributed to predominantly psychological factors.

Q: Can men with concurrent heart problems take sildenafil?

Official labeling strictly prohibits the use of sildenafil (is contraindicated) in patients who are taking organic nitrates in any form or guanylate cyclase stimulators. Official product information notes the importance of a thorough cardiovascular assessment to evaluate the risks of sexual activity.

Q: Is sildenafil use safe in men with diabetes?

Clinical trials included patients with diabetes mellitus. While clinical trials included patients with diabetes mellitus, this condition is listed in regulatory documents as a vascular risk factor for a rare visual side effect.

How to Store and Dispose of Viagra (Sildenafil)

Viagra tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. To maintain product quality, the medication must be kept in the original container, which should remain tightly closed, protecting the tablets from moisture. The packaging requires the product to be stored out of the sight and reach of children.

Disposal

Disposal of unused or expired tablets must follow local regulations. It is strictly required not to dispose of Sildenafil via wastewater (such as flushing it down the toilet or sink). If a drug take-back program is unavailable, the tablets may be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash.